Navigation Links
Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
Date:4/24/2012

PHILADELPHIA, April 24, 2012 /PRNewswire/ -- The Intellectual Property & Science division of Thomson Reuters today announced its commitment to support R&D pharmaceutical leaders with a new oncology application for mobile tablet devices, already in use by AstraZeneca executives. The rich visualization dashboard leverages content from Thomson Reuters Cortellis, the company's flagship life sciences platform, and provides real-time data for clinical oncology drug research and development activities.

"Oncology is critical for pharma, as is evidenced by the World Health Organization's projection that an estimated 13.1 million people will die from cancer in 2030, up from the 7.6 million who died in 2008," said Wendy Hamilton, senior vice president at Thomson Reuters.  "The ability of drug companies to quickly find the most relevant research data and clinical information for their oncology studies, in meetings, on the move or at the bench, will allow them to make faster business decisions and focus on areas where there is unmet need."

The solution provides a series of oncology-based clinical dashboards that provide competitive information that quickly answers common questions in drug development. It is platform independent and accessible via the Internet. Mobile tablet-based devices are the primary method used for accessing the solution.

Users see at-a-glance, side-by-side comparisons of adverse events for drugs already on the market or in clinical trials. They get a deeper understanding of the drugs and how they are being targeted for diseases by segment. The comparisons visualize the level of current research and development activity around an indication, whether by company or mechanism of action, together with information on ongoing clinical trials.

The new applications represent the initial output in an ongoing partnership between Thomson Reuters and AstraZeneca, with other applications due to be released this year. The Thomson Reuters Life Sciences Professional Services team is working on similar innovative projects for other customers too.

Launched in late 2011, Cortellis is the most powerful tool of its kind for biopharmaceutical competitive intelligence, drug pipeline, and drug research and development. For more information on the oncology decision support dashboards and Cortellis, go to http://cortellis.thomsonreuters.com/.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals.  We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial and risk, legal, tax and accounting, intellectual property and science and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs approximately 60,000 people and operates in over 100 countries. For more information, go to www.thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Tablet PC Technology Helps Doctors and Patients Focus on Chemotherapy Side Effects, According to Thomson Healthcare Study
3. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
4. Thomson Healthcare Cancer Profiler Used in Study
5. Thomson Reuters Study Finds Sharp Increase in Use of Sleep Medications by Young Adults
6. General Practitioners Write Most Prescriptions for Mental Health Drugs, According to Study from Thomson Reuters and SAMHSA
7. University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety
8. Thomson Reuters Clinical Surveillance Solution Offers Powerful New Functionality to Improve Clinical Quality and Reduce Costs
9. The University of Hong Kong Chooses ResearcherID By Thomson Reuters to Standardize Research Identifiers
10. Thomson Reuters Launches Pharmacy Intervention Solution for Hospital Pharmacists
11. Americans Losing Confidence in Their Ability to Access and Pay for Healthcare, According to Thomson Reuters Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):